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Abstract 
C-β-D-Glucopyranosyl pyrrole derivatives were prepared in the reactions of pyrrole, 2-, and 3-aryl-
pyrroles with O-peracetylated β-D-glucopyranosyl trichloroacetimidate, while 2-(β-D-glucopyranosyl) 
indole was obtained by a cross coupling of O-perbenzylated β-D-glucopyranosyl acetylene with N-tosyl-
2-iodoaniline followed by spontaneous ring closure. An improved synthesis of O-perbenzoylated 2-(β-D-
glucopyranosyl) imidazoles was achieved by reacting C-glucopyranosyl formimidates with α-
aminoketones. The deprotected compounds were assayed with isoforms of glycogen phosphorylase 
(GP) to show no activity of the pyrroles against rabbit muscle GPb. The imidazoles proved to be the best 
known glucose derived inhibitors of not only the muscle enzymes (both a and b) but also of the 
pharmacologically relevant human liver GPa (Ki = 156 and 26 nM for the 4(5)-phenyl and -(2-naphthyl) 
derivatives, respectively). An X-ray crystallographic study of the rmGPb-imidazole complexes revealed 
structural features of the strong binding, and also allowed to explain the absence of inhibition for the 
pyrrole derivatives. 
 
Keywords: Diabetes type 2; Glycogen phosphorylase inhibitor; C-Glucopyranosyl derivative; Pyrrole; 
Indole; Imidazole. 
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Introduction 
A key player in glycogen metabolism is glycogen phosphorylase (GP; EC 2.4.1.1), an enzyme that 
catalyses glycogen degradation to glucose-1-phosphate (Glc-1-P).1 Three isoforms of GP exist in the 
brain, muscle and liver tissue that share ~80 % sequence homology. GP is controlled by allosteric 
effectors and reversible phosphorylation. It exists in at least two inter-convertible forms, a low activity 
and substrate specificity T state and a high activity and substrate specificity R state, which are in 
equilibrium. Phosphorylation by glycogen phosphorylase kinase (PhK) or the binding of various allosteric 
activators, such as AMP, shift the equilibrium towards the R state. In contrast, dephosphorylation by 
glycogen phosphorylase phosphatase or the binding of inhibitors such as glucose promote the transition 
from the R to T state. The active phosphorylated enzyme (GPa) is the main form of GP in the liver 
whereas the unphosphorylated inactive form (GPb) is the prevalent form in the resting muscle. 
Extensive conformational changes occur in the tertiary structure upon transition from the T to R state.2, 3 
These mainly occur at the inter-subunit interface and result in the rearrangement of the flexible 280s 
loop (residues 282 to 285) from a conformation that blocks access to the catalytic site of the enzyme (T 
state) to one that allows substrate binding (R state). X-ray crystallographic studies have revealed that 
apart from the catalytic site there are other six different ligand binding sites: the allosteric site, the new 
allosteric site, the inhibitor site, the glycogen storage site, the benzimidazole site and the quercetin 
binding site.4, 5 Although AMP binds to both the muscle and the liver enzyme, only the muscle isozyme is 
activated cooperatively.6 There are no insertions or deletions in the sequence of the liver enzyme as 
compared to the muscle and out of the 171 amino acid differences between the two enzymes, 49% (85 
amino-acids) are conservative and most of the amino acid changes are functionally neutral. The active 
site is conserved in both amino acid sequence and structural architecture.6 
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The liver is capable of storing glucose as glycogen and, through a reverse process, to produce and 
release glucose to the blood stream. Therefore, the liver is intimately linked to glycaemic control and 
human liver GP (hlGP) is a validated pharmaceutical target for the discovery of novel antihyperglycaemic 
agents.1, 4, 7 Glycogen phosphorylase inhibitors (GPIs) have been shown to have a pharmaceutical 
potential to combat type 2 diabetes (the non-insulin dependent form of diabetes)8-10 while they were 
also found to display cardioprotective effects11, 12 and anticancer activity13-16 as well as to reduce 
cerebral ischemia.17, 18 The design of GPIs has mainly been focused on derivatives of glucose (the 
physiological inhibitor of the enzyme) and during the last decade, the active site of GP has been probed 
with more than 150 glucose derivatives.1, 4, 19-24 The main goal of the design was to maximize the number 
of interactions with active site residues and thus increase inhibitory potency. In this context much effort 
has been devoted to introduce C-1 substituents suitable to exploit interactions with a hydrophobic cleft 
inside the active site, the so-called β-cavity. As a result of these studies, three compound classes 
emerged as submicromolar inhibitors of GP:19, 23, 24 glucopyranosylidene-spiro-heterocycles, N-acyl-N’-β-
D-glucopyranosyl ureas, and C-β-D-glucopyranosyl heterocycles. A collection of the latter type of 
compounds in Chart 1 allows one to conclude that the presence of a hydrogen-bond donor (HBD) 
heterocycle is in general a better inhibitor than the non-HBD counterpart (compare the pairs 1-2,25, 26 3-
4,27-30 5-6,31 and 7-831). From these series C-β-D-glucopyranosyl imidazoles31 8 have so far shown the 
highest potency against rabbit muscle GPb (rmGPb). Similarly to the other two inhibitor classes, the C-β-
D-glucopyranosyl compounds with a larger aromatic substituent (cf phenyl a vs naphthyl b derivatives in 
Chart 1) proved better inhibitors. 
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Chart 1. C-β-D-Glucopyranosyl heterocycles as 
inhibitors (Ki [μM]) of rabbit muscle glycogen 
phosphorylase b (rmGPb) 
 
  
1 2 
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  7626 
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5   
 
40031 - 
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31031 15831 
7   
 
0.2831 0.03131 
8   
 
 
Synthetic target compounds of this study 
 
 
In this paper we disclose our studies on the preparation of several C-β-D-glucopyranosyl pyrrole 
and indole derivatives to answer the question if heterocycles with one HBD atom would make good 
inhibitors of GP, and present an improved synthesis of 2-(β-D-glucopyranosyl) imidazoles. In addition, 
the latter compounds have been tested against human liver GPa (hlGPa), the pharmaceutical target, and 
the crystal structure of rmGPb in complex with the most efficient compounds have been determined to 
elucidate the structural basis of their inhibitory potency. 
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Results and Discussion 
 
Syntheses 
For the preparation of C-glycosyl pyrroles a generally used method is the reaction of an electron 
rich pyrrole derivative with an electrophilic glycosyl donor. Typically, such reactions of 1H-pyrroles give 
2-glycosylated products.32-34 For the synthesis of the target compounds 2- (11)35 and 3-arylpyrroles 
(12a,36 12b37) were prepared according to previously reported methods. C-glycosylation of 10 and 11 
with O-peracetylated β-D-glucopyranosyl-trichloroacetimidate38 9 in the presence of BF3·OEt2 furnished 
the β-configured (3J1’,2’ > 9 Hz) products 13
33 and 15, respectively, in moderate to high yields as expected 
(Scheme 1). Surprisingly, glycosylation of 3-arylpyrroles 12 took place in the sterically more crowded 2-
position to give 17. The site of C-glucosylation in 15b and 17b was established by 1H-1H NOE experiments 
(Figure 1). In the NMR spectra of 15b the characteristic resonances of H-3 (6.53 ppm, J ≈ 3 Hz), H-4 (6.24 
ppm, J ≈ 3 Hz) and C-3 (106.6 ppm), C-4 (110.2 ppm) indicate the 2,5-disubstituted pyrrole structure,39 
and this is also proved by the observed NOEs. In case of 17b the 2,3-disubstituted pyrrole could not be 
differentiated from a 2,4-disubstituted pyrrole by a simple analysis of 1H (pyrrole-H resonances at 6.43 
and 6.86 ppm J ≈ 2.6 Hz) and 13C (pyrrole CH signals: 109.3, 119.2 ppm) spectra. However, NOE between 
H-4 and H-5 as well as the proximity of the sugar and naphthyl moieties (H-1’‒naphthyl-H NOEs) indicate 
the 2,3-disubstitution of the pyrrole ring. O-Acetyl protecting groups were removed by the Zemplén 
protocol to obtain the test compounds 14, 16, and 18. 
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Scheme 1. Reaction conditions: i) BF3·Et2O, 4 Å molecular sieves, dry CH2Cl2, ‒50 °C to rt; ii) cat. NaOMe 
in MeOH, rt. 
 
 
 
Figure 1. Nuclear Overhauser effects observed in C-glucopyranosylated (2-naphthyl)-pyrroles.  
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Synthesis of 2-glycosyl indoles was studied in detail in the course of the preparation of C-
mannosyl tryptophan and analogous compounds.40 2-(β-D-Glucopyranosyl) indole (23) was prepared by 
adaptation and slight modification of the reported method. O-Perbenzylated glucosyl acetylene41 19 was 
cross-coupled with N-tosyl-2-iodoaniline (20) and cyclized to indole 2140 in one step. Subsequent 
detosylation with Bu4NF and debenzylation by catalytic hydrogenolysis yielded the target 2-β-D-
glucopyranosyl indole 23. 
 
 
 
Scheme 2. Reaction conditions: i) Pd(PPh3)4, CuI, PPh3, dry Et3N, 75 °C, under Ar; ii) Bu4NF, THF, reflux; iii) 
H2 (10 bar), Pd(C), dry EtOAc, rt. 
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In a recent communication we presented the first preparation of 4(5)-aryl-2-(β-D-glucopyranosyl) 
imidazoles 8 (Chart 1) based on the cyclisation of O-perbenzoylated C-β-D-glucopyranosyl formamidine 
with α-bromoketones.31 However, this transformation furnished the protected imidazoles 26 only in low 
yields (10-29 %). In order to find a more efficient procedure for the formation of 26 another ring-closing 
reaction was investigated: ethyl C-β-D-glucopyranosyl formimidate42 (24) was treated with α-amino 
ketones 25 (obtained from the corresponding α-azido ketones as described in the supporting 
information) in anhydrous pyridine providing the desired imidazoles in satisfactory yields (Scheme 3). 
 
O
OR
RO
RO
OR
N
HN
Ar
O
OBz
BzO
BzO
OBz
C
NH
OEt
Ar
a
b
24
26a (R = Bz)
45 %
8a (R = H)
74 %
ii
26b (R = Bz)
42 %
8b (R = H)
77 %
ii
i Ar
O
NH2
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25
 
 
Scheme 3. Reaction conditions: i) dry pyridine, rt; ii) cat. NaOMe in MeOH, rt. 
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Kinetic Studies 
 
The test compounds were evaluated against GPs of various origin and activation state and the 
data are collected in Table 1. The pyrrole derivatives 14, 16, 18, and indole 23 were tested as inhibitors 
of rmGPb, the prototype of GPs,43 by using an assay described previously.44 The pyrroles 14, 16, and 18 
proved inactive in the concentration range studied (the highest applied concentration was 625 μM) 
while indole 23 exhibited very weak inhibition, therefore, these compounds were not investigated 
further. 
 
Since imidazoles 8 were shown to be the strongest glucose derived inhibitors of rmGPb known to 
date,31 the inhibitory potency of 8a and 8b has been evaluated against hlGPa. For comparison purposes 
we also determined their potency with rmGPa and measured the inhibitory potency of α-D-glucose for 
hlGPa. Both compounds 8 are competitive inhibitors with respect to substrate Glc-1-P as revealed by the 
Lineweaver-Burk plots that intersect at the same point on the y-axis for hlGPa and rmGPa. The Ki values 
derived from the Dixon plots (1/v vs [I]) were for 8a 0.156 µM and 0.226 µM for hlGPa and rmGPa, 
respectively. For 8b they were found to be 0.026 μM and 0.065 μM for hlGPa and rmGPa, respectively. 
These values are in agreement with their respective inhibition constants for rmGPb31 and indicate that 
8a and 8b are approximately 27400 and 164600 times, respectively, more potent than α-D-glucose. They 
also indicate that the compound with the 2-naphthyl group is more efficient than its phenyl counterpart. 
Furthermore, it seems that the two compounds do not display any preference for the three isoenzymes 
(hlGPa, rmGPa and rmGPb) since they inhibit all three with similar potency.  
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Table 1. The chemical structures and the inhibition constants of the compounds studied. The 
crystallographic numbering scheme for the inhibitor atoms in D-glucose, 8a, and 8b is also shown. 
Compound 
number 
Chemical Structure Ki (μM) 
  hlGPa rmGPa rmGPb 
α-D-Glc 
 
4280 ± 410 200045 170046 
8a 
 
0.156 ± 0.008 0.226 ± 0.098 0.28031 
8b 
 
0.026 ± 0.006 0.065 ± 0.003 0.03131 
14 
 
ND ND 
no inh. at 
625 µM 
16a 
 
ND ND 
no inh. at 
625 µM 
16b 
 
ND ND 
no inh. at 
625 µM 
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18a 
 
ND ND 
no inh. at 
625 µM 
18b 
 
ND ND 
no inh. at 
625 µM 
23 
 
ND ND IC50 625 μM 
ND: not determined 
 
Structural Studies 
 
The crystal structures of rmGPb in complex with 8a and 8b have been determined at high 
resolution (1.85 Å). Both inhibitors were found bound at the catalytic site with all atoms well defined 
within the electron density map (Fig. 1). The binding of 8a and 8b does not trigger any significant 
conformational change to rmGPb and the r.m.s.d. between the complex structures and the ligand-free 
structure over well-defined residues gave a r.m.s.d. of 0.15 and 0.14 Å for Ca atoms for the 8a and 8b 
complexes, respectively. Upon binding both inhibitors displace four water molecules from the active site 
and they bind in similar structural mode (Fig. 2). The most characteristic feature is the anchoring of their 
β-D-glucopyranose moiety at the rmGPb glucose binding site and its interactions with protein residues 
(Table 2). These are essentially the same with those formed by glucose with rmGPb.47 The imidazole 
linker engages in a hydrogen bond interaction with the main chain oxygen of His377 via N(H)2 and in 
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water mediated interactions with Asp283 side chain via N5. The interaction with the carbonyl oxygen of 
His377 has been previously observed for the amide nitrogen of N-acetyl-β-D-glucopyranosylamine (Ki = 
32 µM),48, 49 of glucopyranosylidene-spirohydantoin (Ki = 3.1 µM),
50, 51 and -thiohydantoin (Ki = 5.1 µM),
52 
β-D-glucopyranosyl formamide analogs (Ki = 310 – 1800 µM),
53 and C-(β-D-glucopyranosyl)benzimidazole 
(Ki = 9 µM).
26 The increased inhibitory potency of these compounds was attributed to the interaction 
with the main chain oxygen of His377 and one of the design goals of 8 was to exploit this interaction. In 
addition, participation of heterocyclic nitrogen atoms in water mediated interactions were observed for 
C-β-D-glucopyranosyl benzimidazole26 (2), 5-methyl-1,3,4-oxadiazole,26, 28 and 5-(2-naphthyl)-1,2,4-
oxadiazole21 (3b) derivatives. In these compounds the nitrogen atoms are in the same position as N5 in 
the imidazoles. A comparison of the inhibitory efficiency of benzimidazole 2 (Ki = 9 μM) and indole 23 
(IC50 ~ 625 μM) shows the practical loss of activity for the latter that may be explained by the absence of 
the second nitrogen in 23 (assuming that the heterocycle is oriented towards the formation of the H-
bond to His377). The absence of this nitrogen in the pyrrole ring may also explain the loss of activity for 
pyrroles 16 and 18 in which the orientation of NH towards His377 places the aromatic residues into 
highly unfavourable positions. The opposite orientation allowing the participation of the ring N in water 
mediated interactions would result in the loss of the H-bonding ability to His377 and this, even if the 
position of the aromatic moieties would be optimal in 16, seems detrimental for the binding.  
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Figure 1. Diagram showing the electron density map of 8a (A) and 8b (B)  before incorporating the 
atomic models of the inhibitors (presented as ball-and-stick-models). 
 
Table 2. Hydrogen bond interactions of 8a, and 8b in the crystal. Numbers shown are distances in Å. 
Inhibitor atom
 
Protein atom 8a 8b 
O2’ Asn284 ND2 3.3 2.9 
 Tyr573 OH 3.1 3.1 
 Glu672 OE1 3.2 3.1 
 Water 2.9      2.9 
 
Water 2.9       3.0 
O3’ Glu672 OE1 2.8 2.7 
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 Ala673 N 3.3 3.3 
 Ser674 N 3.1 3.1 
 
Gly675 N 3.2 3.1 
O4’ Gly675 N 2.9 2.9 
 
Water 2.7       2.6 
O6’ His377 ND1 2.7 2.7 
 
Asn484 ND2 2.8 2.8 
N2 His377 O 2.9 2.9 
N5 Water 2.8 2.8 
Total  15 15 
 
 
The phenyl and the naphthyl groups of 8a and 8b, respectively, bind at the β-cavity engaging in 
numerous van der Waals interactions. Both phenyl and naphthyl are involved in 18 van der Waals 
interactions with Glu88 (1), Asn282 (2), Asn284 (8), Phe285 (2), and His341 (5). In addition, the naphthyl 
group is involved in 11 van der Waals interactions with Asn282 (1), Phe285 (3), Phe286 (1), Arg292 (2), 
His341 (3), and Ala383 (1). The structural basis of the inhibitory potency of the two compounds seems to 
lie on their interactions with the side chains of Asn282, Asp283, and Asp284 which hold the 280s loop in 
its closed T-state conformation, therefore inhibiting access of the substrate to the catalytic site. The 
additional van der Waals interactions of 8b seem to form the structural basis for the significant 
difference in the inhibitory potencies of these two inhibitors.  
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Figure 2. Stereo diagram showing the network of interactions formed between 8a (a) and 8b (b) with 
residues at active site of rmGPb. Hydrogen bond interactions are represented as dotted lines and water 
molecules as blue spheres. 
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Conclusion 
 
Syntheses of a series of C-glucopyranosyl pyrroles, indole, and an improved preparation of C-
glucopyranosyl imidazoles allowed us to study and compare their inhibitory efficiency against isoforms 
of GP. While pyrroles had no effect with rmGPb, imidazoles proved to be the best known glucose 
analogue inhibitors of rmGPb, rmGPa, and also of hlGPa, the physiologically relevant enzyme. Structural 
investigations of the rmGPb-imidazole complexes by X-ray crystallography revealed important 
interactions between the imidazole ring and the protein, such as the H-bridge from N(H)2 to His377 and 
involvement of N5 in water mediated H-bond networks. The absence of the latter interactions in the 
pyrroles may explain why these compounds show no inhibitory activity. 
 
 
Experimental 
 
Syntheses 
 
General methods 
 
Melting points were measured on a Kofler hot-stage and are uncorrected. Optical rotations were 
determined with a Perkin-Elmer 241 polarimeter at rt. NMR spectra were recorded with Bruker 360 
(360/90 MHz for 1H/13C) or Bruker Avance II 500 (500.13/125.76 for 1H/13C) spectrometers. Chemical 
shifts are referenced to Me4Si (
1H), or to the residual solvent signals (13C). Mass spectra were recorded 
with a Thermo LTQ XL mass spectrometer (Thermo Electron Corp., San Jose, CA, USA) operated in a full 
scan positive ion ESI mode. Microanalyses were performed on an Elementar Vario Micro cube 
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instrument. TLC was performed on DC-Alurolle Kieselgel 60 F254 (Merck) plates, visualized under UV light 
and by gentle heating. For column chromatography Kieselgel 60 (Merck, particle size 0.063-0.200 mm) 
was used. EtOAc (P4O10), CH2Cl2 (P4O10) and Et3N (CaH2) were distilled from the given drying agents and 
stored over 4 Å molecular sieves. MeOH was purified by distillation after refluxing for a couple of hours 
with magnesium turnings and iodine. Pyridine (VWR), pyrrole, tetrakis(triphenylphosphine)palladium(0), 
TOSMIC, 2-vinylnaphthalene (Sigma-Aldrich) were purchased from the indicated suppliers. 2,3,4,6-Tetra-
O-acetyl-β-D-glucopyranosyl-trichloroacetimidate38 (9), the 2-aryl-1H-pyrroles35 (11a,b), the 3-aryl-1H-
pyrroles (12a,36 12b37), 2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl-ethyne41 (19), N-tosyl-2-iodoaniline54 
(20), ethyl C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formimidate42 (24) and the 2-azido-1-
arylethanones55 were synthesized according to published procedures. 
 
General procedures 
 
General procedure I for the synthesis of 2-(2’,3’,4’,6’-tetra-O-acetyl-β-D-glucopyranosyl)-pyrroles (13, 
15, 17) 
2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl-trichloroacetimidate (9, 100 mg, 0.2 mmol) and pyrrole (10, 1 
mmol) or the corresponding aryl-pyrrole (11a,b or 12a,b, 0.2 mmol) were dissolved in anhydrous CH2Cl2 
(3 ml) and activated 4 Å molecular sieves (powder, 200 mg) were added. The mixture was cooled to ‒50 
°C and BF3·Et2O (12 μl, 0.1 mmol) was added dropwise with continuous stirring. The reaction was stirred 
for 1h at ‒50 °C, then slowly allowed to reach room temperature and stirred for the given time. After 
total consumption of the trichloroacetimidate (judged by TLC, 1:1 hexane-EtOAc), molecular sieves were 
removed by filtration and the filtrate was purified by column chromatography. 
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General procedure II for the preparation of 2-amino-1-arylethanone hydrochlorides (25) 
To a degassed solution of a 2-azido-1-arylethanone (18.6 mmol) in methanol (100 mL) a solution of 
tin(II) chloride dihydrate (12.65 g, 55.8 mmol) in methanol (160 mL) was added and the mixture was 
stirred at rt under N2 atmosphere. When the TLC (3:1 hexane-EtOAc) showed total consumption of the 
starting material (5-24 h) dry HCl gas was bubbled through the reaction mixture over 12 h. The solution 
was then concentrated under reduced pressure and the residue was put into the freezer for overnight. 
The resulting precipitates were filtered off and washed with cold methanol. The products were used in 
the next step without further purification. 
 
General procedure III for the synthesis of 4(5)-aryl-2-(2’,3’,4’,6’-tetra-O-benzoyl-β-D-glucopyranosyl)-
imidazoles (26) 
Ethyl C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formimidate (24, 0.15 mmol) and the corresponding 
2-amino-1-arylethanone hydrochloride (25, 0.31 mmol, 2 equiv.) were dissolved in anhydrous pyridine 
(4 mL) and the reaction mixture was stirred at rt. After completion of the reaction (1-2 d) monitored by 
TLC (3:2 hexane-EtOAc) the solvent was removed under diminished pressure and the residue was 
purified by column chromatography. 
 
General procedure IV for removal of the O-acetyl protecting groups (for the preparation of test 
compounds 14, 16, 18) 
An O-acetyl protected compound (100 mg) was dissolved in anh. MeOH (5 mL), a few drops of ~1M 
solution of NaOMe in MeOH was added and the mixture was left to stand at rt. After complete 
conversion (judged by TLC, 7:3 CHCl3-MeOH) the reaction mixture was neutralized by the careful 
addition of AcOH and evaporated in vacuo. The crude product was purified by column chromatography. 
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Protein production and purification 
 
Rabbit skeletal muscle glycogen phosphorylase b (rmGPb) was isolated, and purified as described 
previously.56 RmGPa was prepared from rmGPb by phosphorylation with a truncated form of the γ 
(catalytic) subunit of rabbit skeletal muscle phosphorylase kinase produced as described previously.57 
Human liver glycogen phosphorylase a (hlGPa) was expressed from the pET160DEST vector (Invitrogen) 
with a His tag (6x) followed by the Lumio tag and a TEV protease prescission site in E.coli strain BL21 
Gold (DE3) (Agilent Technologies). The strain was inoculated in LB medium (plus 50 μg/mL ampicillin, 
100 mg/L pyridoxine, and 600 mg/L MnCl2) grown at 37 º C to a cell density of OD600= 0.7 and induced for 
15 hr with 0.6 mM isopropyl-1-thio-β-D-galactoside (IPTG) prior to harvest. The E. coli cells were 
resuspended in lysis buffer (50 mM Na2HPO4/NaH2PO4 [pH 8.0], containing 500 mM NaCl, 20 mM 
imidazole, a Protease inhibitor cocktail tablet (EDTA-free, Roche) and 50 U Benzonase) and sonicated at 
4º C. The lysate was clarified by centrifugation at 16,000 × g for 1 hr. hlGPb in the soluble fraction of the 
lysate was purified using a Ni2+ Sepharose chromatography. His-tag tail was removed by cleaving with 
TEV protease and Ni2+ Sepharose chromatography. A final step using anion-exchange chromatography 
led to a pure hlGPb sample as judged by the appearance of a single band in SDS page.Phosphorylation to 
hlGPa was performed using a truncated form of the γ (catalytic) subunit of rabbit skeletal muscle 
phosphorylase kinase. 
 
Kinetic studies 
 
Kinetic studies with hlGPa were performed at 30° C in the direction of glycogen synthesis by measuring 
the inorganic phosphate released in the reaction.56 Briefly, the enzyme (5 µg/ml rmGPb or rmGPa, and 1 
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μg/mL hlGPa) was assayed  in a 30 mM imidazole/HCl buffer (pH 6.8) containing 60 mM KCl, 0.6 mM 
EDTA, and 0.6 mM dithiothreitol using constant concentrations of glycogen (0.2% w/v), AMP (1 mM; 
only for the rmGPb experiments), and various concentrations of Glc-1-P and inhibitors. For the 
measurement of the Ki for α-D-glucose for hlGPa solutions of four different concentrations were used 2 
min after dissolution while the overall assay time was 1 minute following a previously described 
method.46 Initial velocities were calculated from the pseudo-first order rate constants. Kinetic data 
presented in the form of Lineweaver-Burk, or Dixon plots were analysed for the calculation of the kinetic 
parameters by the non-linear regression program GRAFIT.58 
 
X-ray crystallography 
 
Tetragonal T state rmGPb crystals were grown as described previously.59 These crystals belong to space 
group P43212 with unit cell dimensions a=b=128.6 Å and c=116.3 Å. rmGPb – inhibitor complexes were 
formed by diffusion of a 10 mM solution of the inhibitor in the crystallization media (supplemented with 
15% (v/v) DMSO) in preformed rmGPb crystals at room temperature for 6 hours prior to data collection. 
X-ray diffraction data were collected using synchrotron radiation on station ID911-2 at MAX-Lab 
Synchrotron Radiation Source in Lund, Sweden. Crystal orientation, integration of reflections, inter-
frame scaling, partial reflection summation, and data reduction was performed by the program 
Mosflm.60 Scaling and merging of intensities were performed by SCALA.61 Crystallographic refinement of 
the complexes was performed by maximum-likelihood methods using REFMAC.61 The starting model 
employed for the refinement of the complexes was the structure of the native T state rmGPb complex 
determined at 1.9 Å resolution (Leonidas et al., unpublished results). Ligand molecule coordinates and 
topologies were constructed using JLigand62 and they were fitted to the electron density maps after 
adjustment of their torsion angles. Alternate cycles of manual rebuilding with the molecular graphic 
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program COOT61 and refinement with REFMAC63 improved the quality of the models. A summary of the 
data processing and refinement statistics for the inhibitor complex structures is given in Table 2. The 
stereochemistry of the protein residues was validated by MolProbity.64 Hydrogen bonds and van der 
Waals interactions were calculated with the program CONTACT as implemented in CCP461 applying a 
distance cut off 3.3 Å and 4.0 Å, respectively. Figures were prepared with PyMol.65 The coordinates of 
the new structures have been deposited with the RCSB Protein Data Bank (http://www.rcsb.org/pdb) 
with codes presented in Table 3. 
 
Table 3. Summary of the diffraction data processing and refinement statistics for the rmGPb complexes. 
Values in parentheses are for the outermost shell. 
GPb complex 8a 8b 
Data collection and processing statistics 
Resolution  (Å) 38.39 – 1.85 38.76 – 1.85 
Outermost shell (Å) 1.95 – 1.85 1.95 – 1.85 
Reflections measured 323721 (46061) 326554 (46626) 
Unique reflections 82598 (11847) 74394 (11353) 
Multiplicity 3.9 (3.9) 4.4 (4.1) 
Rsymm 0.069 (0.428) 0.111 (0.450) 
Completeness (%) 99.3 (98.7) 89.9 (94.8) 
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<I/σI > 12.2 (3.3) 4.9 (2.6) 
Refinement statistics 
Rcryst 0.158 (0.240) 0.170 (0.240) 
Rfree 0.188 (0.260) 0.203 (0.286) 
No of solvent molecules 321 324 
r.m.s. deviation from ideality  
    in bond lengths (Å) 0.01 0.01 
    in angles (°) 1.3 1.3 
Average B factor (Å2) 
Protein atoms  30.7 29.8 
Solvent molecules  36.9 36.1 
Inhibitor atoms  18.0 17.4 
PDB entry 5JTT 5JTU 
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• Synthesis of C-β-D-glucopyranosyl pyrrole, indole, and imidazole derivatives 
• Nanomolar inhibition of human liver glycogen phosphorylase 
• X-Ray crystallography of glycogen phosphorylase‒C-glucosyl imidazole complexes 
